Successful hematopoietic stem cell transplantation for two patients with relapse of intrachromosomal amplification of chromosome 21-positive B-cell precursor acute lymphoblastic leukemia

Tomoya Harada, Hidemi Toyoda*, Naoki Tsuboya, Ryo Hanaki, Keishiro Amano and Masahiro Hirayama

Department of Pediatrics, Mie University Graduate School of Medicine, Tsu, Japan

In children with relapsed acute lymphoblastic leukemia (ALL), it is essential to identify patients in need of treatment intensification. Minimal residual disease (MRD)-based treatment stratification resulted in excellent survival in children with late relapsed B-cell precursor (BCP)-ALL. Chemotherapy alone produced a favorable outcome in patients with negative MRD after induction. The genetic abnormality also plays an important role in determining the prognosis and stratification for treatment. Intrachromosomal amplification of chromosome 21 (iAMP21) is associated with a poor outcome and a high risk for relapse, and there is no standard treatment after relapse. Herein, we present two patients with relapsed iAMP21-positive ALL who were successfully treated by cord blood transplantation (CBT). Although both patients had late bone marrow relapse and favorable MRD response, CBT was performed due to iAMP21 positive. Patients 1 and 2 have been in remission post-CBT for 15 and 45 months, respectively. Patients with relapsed iAMP21-positive ALL may be considered for stem cell transplantation even in late relapses and favorable MRD response.

KEYWORDS
relapsed acute lymphoblastic leukemia, iAMP21, hematopoietic stem cell transplantation, late bone marrow relapse, minimal residual disease, B-cell precursor acute lymphoblastic leukemia
Introduction

Childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is highly curable, but relapse is the main reason for treatment failure (1, 2). After relapse, the duration of clinical remission from the first diagnosis has been shown to be the strongest predictor of survival, with patients relapsing on or shortly after stopping chemotherapy having the worst outcome (1, 3). For late relapse, minimal residual disease (MRD) levels at the end of induction therapy are predictive of survival. Although allogeneic hematopoietic stem cell transplantation (HSCT) is recommended for patients with a higher MRD level post-induction, those with a low MRD level are allocated to not undergo HSCT and to continue chemotherapy (4, 5).

In pediatric ALL, chromosomal abnormalities are routinely used in risk stratification for treatment, which has substantially contributed to the remarkably improved outcomes of 90% survival for childhood BCP-ALL (2). Intrachromosomal amplification of chromosome 21 (iAMP21) is a recently identified chromosomal abnormality in childhood BCP-ALL, with an incidence of approximately 2% in older children with BCP-ALL (6–11). iAMP21 is detected during routine screening for the presence of the ETV6-RUNX1 fusion by fluorescence in situ hybridization (FISH), and the finding of ≥ 3 extra RUNX1 copies on a single abnormal chromosome 21 (a total of ≥ 5 RUNX1 signals per cell) is currently used to define iAMP21 (8).

Patients newly diagnosed with iAMP21-positive BCP-ALL had poor survival when receiving standard therapy, but benefited from more intensive chemotherapy as a high-risk group (6, 9, 10, 12, 13). However, a standard treatment strategy for relapsed iAMP21-positive BCP-ALL is unknown. Herein, we describe two patients with relapsed iAMP21-positive BCP-ALL who received chemotherapy followed by cord blood transplantation (CBT).

Results

Case 1

A 9-year-old boy was admitted due to fever for two weeks and lumbago. The laboratory results showed a white blood cell (WBC) count of 3.9 × 10^9/L with 0% blast cells, and bone marrow (BM) evaluation showed 50% blast cells with lymphoid characteristics. Immunophenotyping confirmed BCP-ALL. Cytogenetic analysis was performed on a BM sample. G-banded chromosome analysis revealed a male karyotype 46, XY, -21, + mar/46, XY. The poor quality of the metaphase chromosomes restricted their evaluation. The FISH study showed no rearrangements in BCR/ABL1, KMT2A, or ETV6/RUNX1. However, FISH revealed 5–12 signals of RUNX1 in 68% of interphase cells (Figure 1A). There was no extramedullary organ infiltration. He was treated according to the Japanese Pediatric Leukemia/Lymphoma Study Group’s protocol for the standard-risk group (14). Peripheral blood showed good treatment response to prednisolone on day 8, and BM examination after the induction therapy revealed complete remission (CR) and negative for MRD detected by a real-time polymerase chain reaction of antigen receptors (15). Although he had been clinically well for 35 months, he presented pallor and splenomegaly at 11 months after frontline chemotherapy. He had a WBC count of 15.9 × 10^9/L with 66% blast cells and the morphologic evaluation of the BM showed 97.3% lymphoid blast cells. G-banded chromosome analysis of the BM sample revealed a male karyotype 46, XY, -21, + mar. FISH analysis revealed no ETV/RUNX1 fusion signals and five signals for the RUNX1 probe in 96% of the analyzed nuclei (Figure 1B). There was no extramedullary organ infiltration. He was diagnosed with late isolated BM relapse of iAMP21-positive BCP-ALL and treated according to the ALL-R3 mitoxantrone regimen (16). He achieved a second CR after induction chemotherapy and MRD in BM after induction was negative. He received two cycles of a 28-day continuous infusion of blinatumomab at 15 μg/m^2/day, followed by a 4/6 antigen matched unrelated CBT. The myeloablative conditioning regimen consisted of 12-Gy total body irradiation (TBI) from days -9 to -6 (six fractions), intravenous etoposide 15 mg/kg/day from days -5 to -4, and intravenous cyclophosphamide 60 mg/kg/day from days -9 to -6. Tacrolimus and short-term methotrexate were used for graft-versus-host disease (GVHD) prophylaxis. Neutrophil engrafted on day 23 post-CBT. BM examination post-CBT revealed CR with 100% donor-type hematopoiesis. He had a WBC count of 3.9 × 10^9/L with 0% blast cells, and bone marrow (BM) evaluation showed 50% blast cells with lymphoid characteristics. Immunophenotyping confirmed BCP-ALL. Cytogenetic analysis was performed on a BM sample. G-banded chromosome analysis revealed a male karyotype 46, XY, -21, + mar/46, XY. The poor quality of the metaphase chromosomes restricted their evaluation. The FISH study showed no rearrangements in BCR/ABL1, KMT2A, or ETV6/RUNX1. However, FISH revealed 5–12 signals of RUNX1 in 68% of interphase cells (Figure 1A). There was no extramedullary organ infiltration. He was treated according to the Japanese Pediatric Leukemia/Lymphoma Study Group’s protocol for the standard-risk group (14). Peripheral blood showed good treatment response to prednisolone on day 8, and BM examination after the induction therapy revealed complete remission (CR) and negative for MRD detected by a real-time polymerase chain reaction of antigen receptors (15). Although he had been clinically well for 35 months, he presented pallor and splenomegaly at 11 months after frontline chemotherapy. He had a WBC count of 15.9 × 10^9/L with 66% blast cells and the morphologic evaluation of the BM showed 97.3% lymphoid blast cells. G-banded chromosome analysis of the BM sample revealed a male karyotype 46, XY, -21, + mar. FISH analysis revealed no ETV/RUNX1 fusion signals and five signals for the RUNX1 probe in 96% of the analyzed nuclei (Figure 1B). There was no extramedullary organ infiltration. He was diagnosed with late isolated BM relapse of iAMP21-positive BCP-ALL and treated according to the ALL-R3 mitoxantrone regimen (16). He achieved a second CR after induction chemotherapy and MRD in BM after induction was negative. He received two cycles of a 28-day continuous infusion of blinatumomab at 15 μg/m^2/day, followed by a 4/6 antigen matched unrelated CBT. The myeloablative conditioning regimen consisted of 12-Gy total body irradiation (TBI) from days -9 to -6 (six fractions), intravenous etoposide 15 mg/kg/day from days -5 to -4, and intravenous cyclophosphamide 60 mg/kg/day from days -9 to -6. Tacrolimus and short-term methotrexate were used for graft-versus-host disease (GVHD) prophylaxis. Neutrophil engrafted on day 23 post-CBT. BM examination post-CBT revealed CR with 100% donor-type hematopoiesis. He experienced grade II acute GVHD involving the skin only, which was successfully treated with an increased tacrolimus dose. He has been in good condition for the last 15 months following CBT without ALL recurrence.

Case 2

A 15-year-old girl was admitted to the hospital because of petechiae and was diagnosed with BCP-ALL. At the onset of the ALL, the BM sample revealed a female karyotype 46, XX, and FISH analysis for ETV/RUNX1 was not performed. Chemotherapy was started according to the Japan Adult Leukemia Study Group B-ALL213 protocol (17, 18). The patient achieved CR after induction chemotherapy. Although she had been clinically well for 36 months, leukocytopenia

Abbreviations: ALL, Acute lymphoblastic leukemia; BM, Bone marrow; BCP-ALL, B-cell precursor acute lymphoblastic leukemia; CBT, Cord blood transplantation; CR, Complete remission; FISH, Fluorescence in situ hybridization; GVHD, Graft-versus-host disease; HSCT, Hematopoietic stem cell transplantation; iAMP21, Intrachromosomal amplification of chromosome 21; MRD, Minimal residual disease; TBI, Total body irradiation; WBC, White blood cell.
Discussion

We present two late BM relapsed cases of iAMP21-positive BCP-ALL that were successfully treated by CBT. The duration of the first CR and immunophenotypes predict outcomes in patients with relapsed ALL (20). Patients with late BM relapses (BCP-ALL relapses occurring > 6 months after stopping chemotherapy) have relatively favorable survival rates (16, 19). MRD is a highly predictive risk factor in late BM relapses of BCP-ALL and is successfully used for treatment stratification in relapse protocols for childhood ALL (16, 19). Patients with high and low MRD after induction therapy were allocated to undergo allogeneic hematopoietic stem cell transplantation (HSCT) and to receive chemotherapy, respectively (16, 19). Even though both patients had late BM relapses with low MRD after induction, they underwent CBT because of iAMP21 positivity.

In patients with newly diagnosed iAMP21-positive BCP-ALL, the presence of iAMP21 is associated with an increased risk of relapse, and the patients benefited from more intensive frontline therapy as a high-risk group (9, 10, 12). However, a standard treatment strategy for relapsed iAMP21-positive BCP-ALL is unknown. Relapsed iAMP21-positive BCP-ALL was categorized as high-risk cytogenetic groups in the ALL-R3 trial and ALL-REZ BFM 2002 trials (16, 20). In long-term follow-up of late BM relapses in the ALL-R3 trial, progression-free and overall survivals were poor in cytogenetic high-risk groups such as iAMP21, KMT2A, TCF3-PBX1, low hypodiploid (16).

Patients with high-risk relapses (BCP-ALL relapses within 18 months of the first diagnosis or with isolated medullary relapses within 6 months of stopping therapy) have poor event-free survival rates (22.6%) (20). Maintaining a second CR remains a major problem in high-risk BCP-ALL relapses. The second CR after HSCT was maintained in 61 (47%) of 131 patients with a high-risk BCP-ALL relapse (20), showing HSCT benefits survival even in high-risk cases. Thus, relapsed iAMP21 should be treated as a high-risk relapse and might require HSCT even in late relapse and negative MRD cases after induction.

The use of pediatrics-inspired protocols in adolescent and young adults ALL results in superior survival compared with the adult protocols (21). Although adolescents and young adults with ALL are currently treated with pediatric protocols in Japan, case 2 did not have the opportunity to be treated with pediatric protocols at the time of disease onset. Since this might be one of the reasons for relapse, adolescents and young adults with ALL should be treated with pediatric protocols. iAMP21 patients have been shown to clearly benefit from receiving more intensive therapy (9, 10, 12). However, iAMP21 is not assigned to a more intensive regimen in the current Japanese pediatric protocol for newly diagnosed BCP-ALL. Heerema et al. reported that MRD and iAMP21 were independently prognostic in newly diagnosed standard-risk ALL (12). In those trials, standard-risk patients who were MRD negative...
and iAMP21 positive had worse EFS than standard-risk MRD-negative patients without iAMP21 (4-year EFS, 82.2% ± 9.0% vs 94.2% ± 0.5%, respectively, P < 0.001) (12). Moreover, late complications such as secondary cancers and organ-specific complications after HSCT substantially contribute to long-term morbidity and mortality (22). Therefore, to avoid disease relapse and late HSCT effects, newly diagnosed iAMP21 cases should receive intensive frontline chemotherapy as a high-risk group, even if they had good MRD response at end induction.

In order to know whether there were other iAMP21 positive patients with BCP-ALL, the medical records of patients diagnosed with BCP-ALL between 2012 and 2021 in Mie University Hospital were retrospectively reviewed. Although FISH images for ETV6/RUNX1 performed in 42 patients were evaluated, other iAMP21 positive patients were not identified. A nationwide survey is necessary to determine the incidence and prognosis of iAMP21 in patients with BCP-ALL in Japan.

In conclusion, patients with iAMP21-positive BCP-ALL relapse could be successfully rescued by HSCT. Further clinical trials are needed to determine the appropriate treatment for patients with iAMP21-positive BCP-ALL relapse.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

Written informed consent was obtained from the individual(s), and minor(s)’ legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.

Acknowledgments

We are grateful to our patients for being a part of this important work. We thank Enago (www.enago.jp) for the English language review.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Author contributions

TH participated in data collection, analyzed, interpreted the data, performed the analysis, and wrote the manuscript. HT conceived and designed the analysis, supervised data collection, analyzed, interpreted the data, and wrote the manuscript. NT, RH, and KA participated in data collection, analyzed, and interpreted the data. MH conceptualized the study, supervised data collection, and reviewed the manuscript. All authors approved the final manuscript as submitted and agreed to be accountable for all aspects of the work.

References

1. Lew G, Chen Y, Lu X, Rheingold SR, Whitlock JA, Devidas M, et al. Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children’s Oncology Group phase III study AALL0433. Haematologica. (2021) 106:46–55. doi: 10.3324/haematol.2019.237230

2. Oskarsson T, Söderhäll S, Arvidsson J, Forestier E, Montgomery S, Bottai M, et al. Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome. Haematologica. (2016) 101:68–76.

3. Roy A, Cargill A, Love S, Moorman AV, Stoneham S, Lim A, et al. Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial. Br J Haematol. (2005) 130:67–75. doi: 10.1111/j.1365-2410.2005.05572.x

4. Eckert C, Henze G, Seeger K, Hagedorn N, Mann G, Panzer-Grümayer R, et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol. (2013) 31:2736–42. doi: 10.1200/JCO.2012.48.5680

5. Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. (2010) 376:2009–17. doi: 10.1016/S0140-6736(10)62002-8

6. Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, et al. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Münster (ALL-BFM) trials. J Clin Oncol. (2008) 26:3046–50. doi: 10.1200/JCO.2008.16.1117

7. Harrison CJ. Blood Spotlight on iAMP21 acute lymphoblastic leukemia (ALL), a high-risk pediatric disease. Blood. (2015) 125:1383–6. doi: 10.1182/blood-2014-08-569228

8. Harrison CJ, Moorman AV, Schwab C, Carroll AJ, Raetz EA, Devidas M, et al. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia. (2014) 28:1015–21. doi: 10.1038/leu.2013.317
9. Moorman AV, Richards SM, Robinson HM, Strefford JC, Gibson BE, Kinsey SE, et al. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood. (2007) 109:2327–30. doi: 10.1182/blood-2006-08-040436

10. Moorman AV, Robinson H, Schwab C, Richards SM, Hancock J, Mitchell CD, et al. Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials. J Clin Oncol. (2013) 31:3389–96. doi: 10.1200/JCO.2013.48.9377

11. Rand V, Parker H, Russell LJ, Schwab C, Ensor H, Irving J, et al. Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. Blood. (2011) 117:6848–55. doi: 10.1182/blood-2011-01-329961

12. Heerema NA, Carroll AJ, Devidas M, Loh ML, Borowitz MJ, Gastier-Foster JM, et al. Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children’s oncology group studies: a report from the children’s oncology group. J Clin Oncol. (2013) 31:3397–402. doi: 10.1200/JCO.2013.49.1308

13. Robinson HM, Broadfield ZJ, Cheung KL, Harewood L, Harris RL, Jalali GR, et al. Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia. (2003) 17:2249–50.

14. Koh K, Kato M, Saito AM, Kada A, Kawasaki H, Okamoto Y, et al. Phase II/III study in children and adolescents with newly diagnosed B-cell precursor acute lymphoblastic leukemia: protocol for a nationwide multicenter trial in Japan. Jpn J Clin Oncol. (2018) 48:684–91. doi: 10.1093/jjco/hyy071

15. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen J. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. (2003) 17:1013–34. doi: 10.1038/sj.leu.2402922

16. Parker C, Krishnan S, Hamadeh L, Irving JA, Kuiper RP, Rêvész T, et al. Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial. Lancet Haematol. (2019) 6:e204–16. doi: 10.1016/S2352-3026(19)30003-1

17. Hayakawa F, Sakura T, Yujiri T, Kondo E, Fujimaki K, Sasaki O, et al. Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukaemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J. (2014) 4:e232. doi: 10.1038/bcj.2014.72

18. Sakura T, Hayakawa F, Sugiuira I, Murayama T, Imai K, Usui N, et al. High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG. Leukemia. (2018) 32:626–32. doi: 10.1038/Leu.2017.283

19. Eckert C, Groeneveld-Krentz S, Kirschner-Schwabe R, Hagedorn N, Chen-Santel C, Bader P, et al. Improving stratification for children with late bone marrow B-cell acute lymphoblastic leukemia relapses with refined response classification and integration of genetics. J Clin Oncol. (2019) 37:3493–506. doi: 10.1200/JCO.2019.04694

20. Eckert C, Parker C, Moorman AV, Irving JA, Kirschner-Schwabe R, Groeneveld-Krentz S, et al. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. Eur J Cancer. (2021) 151:175–89. doi: 10.1016/j.ejca.2021.03.034

21. Rajendra A, Jain H, Bondha VNA, Nayak I, Tembhare P, Shetty D, et al. Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol. Blood Adv. (2021) 5:1178–93. doi: 10.1182/bloodadvances.2020035326

22. Majhail NS. Long-term complications after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. (2017) 10:220–7.